[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591724":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":36,"centralContacts":41,"locations":47,"responsibleParty":68,"collaborators":23,"id":70,"slug":23,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":23,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":23,"enrollmentInfo":78,"targetDuration":23,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":23,"overallStatus":50,"whyStopped":23,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"National Medical Research Radiological Centre of the Ministry of Health of Russia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Nivo40-AVD","EXPERIMENTAL","Nivolumab 40 mg IV day 1 and 15; Doxorubicin 25 mg\u002Fm2 IV day 1 and 15; Vinblastine 6 mg\u002Fm2 IV day 1 and 15; Dacarbazine 375 mg\u002Fm2 day 1 and 15",[13,14,15,16],"Drug: Nivolumab","Drug: Doxorubicin","Drug: Vinblastine","Drug: Dacarbazine",[18,24,28,32],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Nivolumab","40 mg day 1 and 15",[9],null,{"type":19,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"Doxorubicin","25 mg\u002Fm2 day 1 and 15",[9],{"type":19,"name":29,"description":30,"armGroupLabels":31,"otherNames":23},"Vinblastine","6 mg\u002Fm2 (not exceeding 10 mg) day 1 and 15",[9],{"type":19,"name":33,"description":34,"armGroupLabels":35,"otherNames":23},"Dacarbazine","375 mg\u002Fm2 day 1 and 15",[9],[37],{"name":38,"affiliation":39,"role":40},"Andrey Kaprin","FSBI \"National Medical Research Radiological Centre\" (NMRRC) of the Ministry of Health of the Russian Federation","STUDY_CHAIR",[42],{"name":43,"role":44,"phone":45,"phoneExt":23,"email":46},"Mobil Akhmedov, MD, PhD","CONTACT","79261802399","mobilakhmedov@gmail.com",[48],{"facility":49,"status":50,"city":51,"state":23,"zip":23,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI \"National Medical Research Radiological Centre\" (NMRRC) of the Ministry of Health of the Russian Federation","RECRUITING","Moscow","Russia",{"type":54,"coordinates":55},"Point",[56,57],37.61781,55.75204,{"lat":57,"lon":56},[60,61,64,67],{"name":43,"role":44,"phone":45,"phoneExt":23,"email":46},{"name":62,"role":63,"phone":23,"phoneExt":23,"email":23},"Andrey Kaprin, Prof.","PRINCIPAL_INVESTIGATOR",{"name":65,"role":66,"phone":23,"phoneExt":23,"email":23},"Alexander Fedenko, Prof.","SUB_INVESTIGATOR",{"name":43,"role":66,"phone":23,"phoneExt":23,"email":23},{"type":69,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100591724",false,"NCT06984146","Nivo40-AVD for Advanced Classic Hodgkin Lymphoma","Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma\n2. No past history of autoimmune disease\n3. Age \\> 18 years\n4. Ejection fraction \\> 50%\n5. ECOG 0-4\n\nExclusion Criteria:\n\n1. Organ failure (e.g. creatinine \\> 2x ULN; ALT or AST \\> 5x ULN; bilirubin \\> 2x ULN; hemodynamic instability; respiratory failure \\> Grade 1)\n2. Uncontrolled infection\n3. Pregnancy\n4. Inability to sign informed consent","ALL","18 Years",{"count":79,"type":80},54,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma",[86],"Hodgkin Lymphoma, Adult","2025-11-20",{"date":89,"type":90},"2025-11-26","ACTUAL",{"date":92,"type":90},"2025-04-15",{"date":94,"type":80},"2029-01",{"name":5,"class":6},1]